logo
#

Latest news with #SMITH

Charter Communications, Inc. (CHTR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Charter Communications, Inc. (CHTR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

timea day ago

  • Business
  • Business Wire

Charter Communications, Inc. (CHTR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Charter Communications, Inc. ('Charter' or the 'Company') (NASDAQ: CHTR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CHARTER COMMUNICATIONS, INC. (CHTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024, when adjusted to remove the prior year's impact of ACP related disconnected. The Company's total video customers also decreased by 80,000. On this news, Charter's stock price fell $70.25, or 18.5%, to close at $309.75 per share on July 25, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Charter securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Easterly ROCMuni High Income Municipal Bond Fund (RMHIC, RMHVX, RMJAX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Easterly ROCMuni High Income Municipal Bond Fund (RMHIC, RMHVX, RMJAX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time5 days ago

  • Business
  • Business Wire

Easterly ROCMuni High Income Municipal Bond Fund (RMHIC, RMHVX, RMJAX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund ('Easterly' or the 'Fund') (NASDAQ: RMHIX, RMHVX, RMJAX) investors concerning the Fund's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EASTERLY ROCMUNI HIGH INCOME MUNICIPAL BOND FUND (RMHIC, RMHVX, RMJAX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On June 13, 2025, the Fund abruptly slashed the value of its shares by 30%, with the value of shares continuing to fall in subsequent days. Industry news source The Bond Buyer reported the collapse was indicative of Fund-specific issues like 'flawed pricing,' 'illiquidity,' and the fact that the Fund was insufficiently 'diversified.' The article further noted that the Fund was heavily invested in junk investments with a 'lack of credit transparency.' According to the article, many bonds traded at a massive discount to their previously evaluated prices, including one instance where an investor paid just four cents for what had previous been represented as $3.2 million in bonds for a metal recycling company. The total net assets of the Fund have collapsed from over $230 million as of March 31, 2025 to less than $17 million as of July 8, 2025. Contact Us To Participate or Learn More: If you purchased Easterly shares, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action

Globe and Mail

time5 days ago

  • Business
  • Globe and Mail

Law Offices of Howard G. Smith Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) common stock between January 5, 2023 through June 3, 2025, inclusive (the 'Class Period'). Neogen investors have until September 16, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On January 10, 2025, Neogen disclosed that its second quarter GAAP net income was significantly negative due to a $461 million non-cash goodwill impairment charge related to its acquisition of the 3M Company ('3M'). The Company also revised its full year outlook, cutting revenue and EBITDA guidance. Further, the Company also revealed that as of November 30, 2024, it had material weaknesses in its internal control over financial reporting. On this news, Neogen's stock price fell $0.71, or 5.4%, to close at $12.36 per share on January 10, 2025, thereby injuring investors. Then, on April 9, 2025, Neogen disclosed that quarterly revenue had fallen 3.4% due, in part, to integration issues. The Company also further cut its full year revenue and EBITDA outlook and revealed that its CEO would be stepping down. On this news, Neogen's stock price fell $2.02, or 28.7%, to close at $5.02 per share on April 9, 2025. Then, on June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the integration with 3M was plagued with inefficiencies that Defendants knew would necessitate a goodwill impairment and would impact capital expenditures, revenues, and EBITDA margins; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Neogen common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at:

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time5 days ago

  • Business
  • Business Wire

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Telix Pharmaceuticals Limited ('Telix' or the 'Company') (NASDAQ: TLX) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TELIX PHARMACEUTICALS LIMITED (TLX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 22, 2025, Telix disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) 'seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates.' On this news, Telix's stock price fell $1.70, or 10.4%, to close at $14.58 per share on July 23, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Telix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Biohaven Ltd. (BHVN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Biohaven Ltd. (BHVN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time17-07-2025

  • Business
  • Business Wire

Biohaven Ltd. (BHVN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOHAVEN LTD. (BHVN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors. Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025. Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025. Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased Biohaven securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store